Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Patients with stage IIIB and IV lung adenocarcinoma and progression to first-line
chemotherapy were enrolled to receive afatinib 40 mg/day. Mutational EGFR and HER-2 status
were assessed by RT-PCR. HER2 amplification was evaluated by FISH. Plasma HGF levels were
measured by ELISA before and 2 months (mo) after the start of treatment. We assessed changes
in serum HGF levels and their association with objective response rate (ORR), PFS and overall
survival (OS).